{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:33:54Z","timestamp":1786736034300,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2019]]},"DOI":"10.4103\/jcrt.jcrt_990_19","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T05:44:58Z","timestamp":1578635098000},"page":"1629","source":"Crossref","is-referenced-by-count":39,"title":["Camrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer"],"prefix":"10.4103","volume":"15","author":[{"given":"Xin","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigeng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.275570-1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.21147\/j.issn.1000-9604.2018.06.02","article-title":"Incidence and mortality of lung cancer in China, 2008-2012","author":"Liu","year":"2018","journal-title":"Chin J Cancer Res"},{"key":"key-10.4103\/0973-1482.275570-2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-4","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in advanced Nonsquamous non-small-cell lung cancer","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-5","first-page":"743","article-title":"Pembrolizumab for the treatment of nonsmall cell lung cancer: Current status and future directions","author":"Qin","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275570-6","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"key-10.4103\/0973-1482.275570-8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab:First global approval","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"key-10.4103\/0973-1482.275570-9","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-10","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-11","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-12","doi-asserted-by":"crossref","unstructured":"Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: A phase 2 trial. JAMA oncology 2019. doi: 10.1001\/jamaoncol.2019.1449.","DOI":"10.1001\/jamaoncol.2019.1449"},{"key":"key-10.4103\/0973-1482.275570-13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.275570-14","first-page":"683","article-title":"Repeated percutaneous microwave ablation for local recurrence of inoperable Stage I nonsmall cell lung cancer","author":"Yang","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275570-15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4103\/jcrt.JCRT_269_18","article-title":"Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: A pilot study","author":"Yang","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275570-16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00270-014-0895-0","article-title":"Microwave ablation in combination with chemotherapy for the treatment of advanced non-small cell lung cancer","author":"Wei","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key-10.4103\/0973-1482.275570-17","first-page":"464","article-title":"Microwave ablation plus chemotherapy improved progression-free survival of advanced non-small cell lung cancer compared to chemotherapy alone","author":"Wei","year":"2015","journal-title":"Med Oncol"},{"key":"key-10.4103\/0973-1482.275570-18","doi-asserted-by":"crossref","first-page":"e3998","DOI":"10.1097\/MD.0000000000003998","article-title":"Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study","author":"Ni","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0973-1482.275570-19","doi-asserted-by":"crossref","unstructured":"Ni Y, Ye X, Yang X, Huang G, Li W, Wang J, et al. Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment. J Cancer Res Clin Oncol 2019. doi: 10.1007\/s00432-019-03043-6.","DOI":"10.1007\/s00432-019-03043-6"},{"key":"key-10.4103\/0973-1482.275570-20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1158\/1078-0432.CCR-15-1352","article-title":"PD-1 blockade boosts radiofrequency ablation-elicited adaptive immune responses against tumor","author":"Shi","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key-10.4103\/0973-1482.275570-21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.diii.2017.12.011","article-title":"Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model","author":"Zhu","year":"2018","journal-title":"Diagn Interv Imaging"},{"key":"key-10.4103\/0973-1482.275570-22","doi-asserted-by":"crossref","first-page":"e13112","DOI":"10.1097\/MD.0000000000013112","article-title":"A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer","author":"Yin","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"key-10.4103\/0973-1482.275570-23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1148\/radiol.14132958","article-title":"Image-guided tumor ablation: Standardization of terminology and reporting criteria-a 10-year update","author":"Ahmed","year":"2014","journal-title":"Radiology"},{"key":"key-10.4103\/0973-1482.275570-24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4103\/jcrt.JCRT_221_18","article-title":"Expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors (2018 edition)","author":"Ye","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275570-25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/0973-1482.275570-26","doi-asserted-by":"crossref","first-page":"9048","DOI":"10.1200\/JCO.2017.35.15_suppl.9048","article-title":"Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: A prospective, randomized, control, phase III clinical trial","author":"Wei","year":"2017","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.275570-27","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":", Lee JJ, Hernandez M, Ye R, Camidge DR, et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study","author":"Gomez","year":"2016","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/0973-1482.275570-28","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"key-10.4103\/0973-1482.275570-29","first-page":"827","article-title":"Efficacy and safety of microwave ablation in the treatment of patients with oligometastatic non-small-cell lung cancer: A retrospective study","author":"Wei","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"key-10.4103\/0973-1482.275570-30","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3892\/etm.2015.2681","article-title":"Multiple courses of immunotherapy with different immune cell types for patients with hepatocellular carcinoma after microwave ablation","author":"Yu","year":"2015","journal-title":"Exp Ther Med"},{"key":"key-10.4103\/0973-1482.275570-31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.4103\/jcrt.JCRT_775_17","article-title":"Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma","author":"Zhou","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"key-10.4103\/0973-1482.275570-32","doi-asserted-by":"crossref","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, et al. A single-arm, multicenter, phase ii study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res 2019. doi: 10.1158\/1078-0432.CCR-19-1680.","DOI":"10.1158\/1078-0432.CCR-19-1680"},{"key":"key-10.4103\/0973-1482.275570-33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","author":"Huang","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:36:27Z","timestamp":1786732587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_990_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"alternative-id":["275570"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_990_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}